BidaskClub lowered shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a report published on Thursday morning.

Several other equities analysts have also commented on VYGR. Canaccord Genuity set a $35.00 target price on Voyager Therapeutics and gave the company a buy rating in a research note on Tuesday, May 29th. HC Wainwright started coverage on Voyager Therapeutics in a research note on Monday, June 4th. They issued a buy rating and a $30.00 target price for the company. BTIG Research reiterated a buy rating and issued a $32.00 target price on shares of Voyager Therapeutics in a research note on Thursday, June 7th. Chardan Capital reiterated a hold rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, June 21st. Finally, ValuEngine upgraded Voyager Therapeutics from a buy rating to a strong-buy rating in a research note on Monday, July 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $31.09.

NASDAQ VYGR opened at $18.21 on Thursday. Voyager Therapeutics has a fifty-two week low of $11.54 and a fifty-two week high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.58 million during the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. equities analysts anticipate that Voyager Therapeutics will post -3.19 EPS for the current fiscal year.

In other news, Director Glenn Pierce purchased 5,000 shares of the company’s stock in a transaction on Wednesday, September 12th. The stock was bought at an average cost of $18.44 per share, for a total transaction of $92,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James A. Geraghty purchased 3,000 shares of the company’s stock in a transaction on Friday, August 17th. The shares were purchased at an average price of $18.31 per share, with a total value of $54,930.00. Following the completion of the purchase, the director now directly owns 73,588 shares of the company’s stock, valued at $1,347,396.28. The disclosure for this purchase can be found here. Insiders have acquired 11,000 shares of company stock valued at $205,300 over the last 90 days. 33.60% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the business. BB Biotech AG increased its stake in Voyager Therapeutics by 27.1% during the second quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock worth $49,488,000 after acquiring an additional 540,000 shares during the last quarter. BlackRock Inc. increased its stake in Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock worth $36,066,000 after acquiring an additional 407,677 shares during the last quarter. Farallon Capital Management LLC increased its stake in Voyager Therapeutics by 35.9% during the first quarter. Farallon Capital Management LLC now owns 890,000 shares of the company’s stock worth $16,723,000 after acquiring an additional 235,188 shares during the last quarter. Millennium Management LLC increased its stake in Voyager Therapeutics by 124.0% during the first quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after acquiring an additional 342,148 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Voyager Therapeutics by 15.2% in the second quarter. Wells Fargo & Company MN now owns 450,480 shares of the company’s stock worth $8,802,000 after buying an additional 59,497 shares during the period. Institutional investors own 89.65% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.